8 completed, 2 withdrawn, 1 recruiting. 5 Phase 3, 5 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Withdrawn 2, Recruiting 1 |
| Phase 4 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow Fidec Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants nOPV2 - Poliomyelitis | Phase 3 | Recruiting | Fidec Corporation | 740 | 2026-04-30 | 2026-09-09 |
| A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 nOPV2 - Poliomyelitis | Phase 4 | Completed | Fidec Corporation | 501 | 2023-11-09 | 2026-09-03 |
| Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants nOPV2 - Poliomyelitis | Phase 3 | Completed | Fidec Corporation | 905 | 2021-12-16 | 2024-08-23 |
| Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine bOPV and nOPV2 - Poliomyelitis | Phase 3 | Withdrawn | Fidec Corporation | 2020-12-01 | 2022-01-14 | |
| A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine nOPV2 (monovalent oral polio vaccine) - Poliomyelitis | Phase 2 | Completed | Fidec Corporation | 1025 | 2018-12-04 | 2024-01-19 |
| A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV IPV, f-IPV - Poliomyelitis | Phase 3 | Completed | Fidec Corporation | 773 | 2017-10-23 | 2023-07-21 |
| A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine IPV, f-IPV - Poliomyelitis | Phase 3 | Withdrawn | Fidec Corporation | 2017-07-01 | 2017-06-27 | |
| A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Sabin mOPV2 - Poliomyelitis | Phase 4 | Completed | Fidec Corporation | 100 | 2015-11-01 | 2020-01-14 |
| A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Oral Polio Vaccine - Poliomyelitis | Phase 4 | Completed | Fidec Corporation | 154 | 2015-11-01 | 2023-04-18 |
| A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children SABIN monovalent OPV2 - Adverse Event Following Immunisation | Phase 4 | Completed | Fidec Corporation | 164 | 2015-10-01 | 2020-08-14 |
| Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Bivalent Oral Polio Vaccine (bOPV), Trivalent Oral Polio Vaccine (tOPV), Monovalent Oral Polio Vaccine Type 2 (mOPV2) - Poliomyelitis | Phase 4 | Completed | Fidec Corporation | 1420 | 2013-05-01 | 2015-08-06 |
Poliomyelitis (10)
Poliovirus Vaccine, Oral (1) · Rabies Vaccines (1)
Dominican Republic (3) · Panama (3) · Bangladesh (2) · Colombia (1) · Guatemala (1)
Edwin J Asturias, MD (1) · Khaelqu Zaman, Dr. (1) · Luis Rivera, MD (1) · Ricardo Ruttimann, MD (1) · Stella Gutierrez, MD (1) · Vytautas Usonis, Prof (1) · Xavier M Saez-Llorens, MD (1)
PMID 33308427, PMID 36332645, PMID 40318674, PMID 27212429, PMID 28455172, PMID 32621741, PMID 33284114, PMID 38109921, PMID 42610930